Cerebrolysin
Cerebrolysin (Porcine Brain-Derived Neuropeptide Mixture)
Cerebrolysin is a standardised mixture of low-molecular-weight neuropeptides and amino acids derived from porcine brain cortex. It is approved and marketed in over 50 countries (including Germany, China, and Russia) for Alzheimer's disease, ischaemic stroke, traumatic brain injury, and vascular dementia. Its multi-target neuroprotective and neurotrophic profile — mimicking the effects of multiple endogenous neurotrophins simultaneously — makes it uniquely positioned among cognitive compounds.
Mechanism of Action
Cerebrolysin's mechanism is attributed to its low-molecular-weight peptide fraction, which crosses the blood-brain barrier and exerts BDNF-like, NGF-like, and VEGF-like neurotrophic effects. It stimulates neuroplasticity, supports synaptic density, and reduces neuroinflammatory cytokine production.
In Alzheimer's disease models, Cerebrolysin reduces amyloid-beta aggregation, inhibits tau hyperphosphorylation, and decreases neuronal apoptosis through activation of MAPK and PI3K/Akt survival pathways. These multi-target effects are consistent with its neuropeptide complexity.
Cerebrolysin also promotes angiogenesis in cerebral tissue, neurogenesis (new neuron formation from stem cells), and synaptic remodelling. This broad neurotrophic profile accounts for its observed benefits across diverse neurological conditions — from acute stroke recovery to chronic neurodegeneration.
Research Evidence
Cerebrolysin has one of the most extensive clinical research programmes of any nootropic compound, with over 100 controlled trials across Alzheimer's disease, stroke, TBI, and vascular dementia. Evidence is mixed across studies but positive trends are consistent.
Cerebrolysin Meta-Analysis in Alzheimer's Disease
Meta-analysis of 6 RCTs (n=1,535 AD patients): Cerebrolysin produced significant improvements in cognitive global measures and activities of daily living versus placebo, with effects maintained at 6-month follow-up.
Cerebrolysin in Acute Ischaemic Stroke
Multicentre RCT (n=1,070): Cerebrolysin 30ml/day IV for 10 days after acute ischaemic stroke produced significant neurological recovery (NIHSS improvement) and functional outcome improvements at 90 days versus placebo.
Typical Research Protocol
IV administration is the established route for clinical efficacy — the 10–30 mL dose must be diluted in saline and infused slowly over 15–60 minutes. IM administration at lower volumes is used for maintenance protocols. Self-administration is generally not recommended given IV requirement — typically administered in clinical settings.
Safety Profile
Reported Side Effects
- Injection site pain (IM)
- Agitation or anxiety (initial — dose-dependent)
- Headache
- Dizziness
- Hyperthermia (rare)
- Nausea
Contraindications
- Epilepsy/status epilepticus (can lower seizure threshold)
- Severe renal impairment
- Known hypersensitivity to porcine products
- Pregnancy
- Acute psychosis
Common Research Stacks
Frequently Asked Questions
Is Cerebrolysin legal in the US?
Cerebrolysin is not FDA-approved and is not available through licensed US pharmacies. It is approved and sold as a registered pharmaceutical in Germany, Austria, China, Russia, and 50+ other countries. In the US it falls in the research chemical category — import for personal use is a grey area. It is widely obtained through international pharmacies by US researchers.
What conditions has Cerebrolysin been clinically studied for?
Cerebrolysin has RCT evidence across: Alzheimer's disease (multiple studies, positive cognitive and functional outcomes), ischaemic stroke (improved neurological recovery in acute and subacute phases), traumatic brain injury (improved functional recovery), vascular dementia, and ADHD. It is approved for clinical use in stroke and Alzheimer's disease in multiple countries.
How does Cerebrolysin compare to other cognitive peptides like Semax?
Cerebrolysin is a complex mixture providing multi-factor neurotrophic support (NGF-like, BDNF-like, VEGF-like). Semax is a single, defined heptapeptide acting primarily via BDNF upregulation and dopaminergic modulation. Cerebrolysin is better suited for neurological disease, neurodegeneration, and severe cognitive impairment — where multi-target neurotrophism matters most. Semax is better for cognitive enhancement and neuroprotection in healthier individuals.
Can Cerebrolysin be self-administered?
The primary clinical route is IV infusion, which requires training, sterile technique, and ideally medical supervision. Some protocols use IM injection, which can be self-administered with proper training. IV self-administration is not recommended outside clinical supervision. The practical barrier of IV requirement means Cerebrolysin is most commonly used in supervised clinical settings.
How often should Cerebrolysin courses be repeated?
Clinical protocols typically use 10–20 day intensive IV courses, repeated every 3–6 months. For Alzheimer's disease maintenance, some practitioners use quarterly courses. For post-stroke recovery, the acute phase course may be followed by monthly maintenance IM injections. The compound does not produce tolerance or dependence, so repeat courses maintain effectiveness.
Key Research References
- Gauthier S et al. (2020). Cerebrolysin in Alzheimer's disease: a meta-analysis. J Neural Transm.
- Muresanu DF et al. (2016). A randomised, multicentre clinical trial of Cerebrolysin in patients with ischaemic stroke. Cerebrovasc Dis.
Explore more Cognitive research compounds
Browse Cognitive →